Drugs / BI-1910
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06205706 | Dec 2023 → Jul 2027 expected | hepatocellular carcinoma, non-small cell lung carcinoma | BioInvent International AB | Active not recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 8
| Date | Issuer | Release |
|---|---|---|
| 2026-08-20 | BioInvent International AB | Results BioInvent Announces Publication of Preclinical Manuscript on BI-1808 and BI-1910 in Cancer Research bioinvent.com ↗ |
| 2025-11-07 | BioInvent International AB | Results BioInvent's BI-1910 Data Validates TNFR2 as a Novel Immunotherapy Approach in Advanced Solid Tumors: Phase 1 Data at SITC 2025 bioinvent.com ↗
Twelve patients achieved stable disease, whereof five with disease control lasting over six months; this correlates with strong CD4⁺ and CD8⁺ memory T-cell expansion |
| 2025-01-08 | BioInvent International AB | Results BioInvent announces promising data for BI-1910 as single agent from Phase 1 study in solid tumors bioinvent.com ↗
Out of the 12 currently evaluable patients, 6 patients display stable disease. |
| 2024-07-30 | BioInvent International AB | Regulatory BioInvent receives Notice of Allowance from USPTO for BI-1910 patent application bioinvent.com ↗
today announced that the US Patent and Trademark office (USPTO) has issued a Notice of Allowance for a patent application relevant to the anti-TNFR2 antibody BI-1910 |
| 2023-10-31 | BioInvent International AB | Results BioInvent presents preclinical data at SITC providing clear evidence of the potential of anti-TNFR2 antibody BI-1910 bioinvent.com ↗
BI-1910 induced strong anti-tumoral immune responses across a number of preclinical in vivo studies. |
| 2023-06-02 | BioInvent International AB | Regulatory BioInvent obtains IND approval for clinical trial with anti-TNFR2 antibody BI-1910 bioinvent.com ↗
BioInvent International AB (“BioInvent”) (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer immunotherapy, today announces it has received Investigational New Drug (IND) approval for the monoclonal antibody BI-1910, which will now become its second anti-tumor necrosis factor receptor 2 (TNFR2) program to enter clinical development. |
| 2020-06-22 | BioInvent International AB | Results BioInvent presents proof-of-concept data for two TNFR2-targeting antibodies bioinvent.com ↗
Both antibodies showed significant antitumor activity in several immunocompetent models |
| 2020-05-15 | BioInvent International AB | Results BioInvent expands anti-TNFR2 program by selecting second monoclonal antibody for further development bioinvent.com ↗
Targeting TNFR2 demonstrates compelling therapeutic effects in syngeneic solid cancer models spanning "hot" and "cold" tumors. |
All press releases naming this drug 13 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BI-1910 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06205706 ↗ |
| Modality | Monoclonal antibody | “BI-1910, a Monoclonal Antibody to Tumor Necrosis Factor Receptor 2 (TNFR2)” NCT06205706 ↗ |
| Route | Intravenous | “flat-dose IV infusion” NCT06205706 ↗ |